SEC filings and other documents

All proposals, including director elections and plan amendments, were approved by stockholders.

Record Q2 revenue and subscription growth, with improved margins and reaffirmed full-year guidance.

Subscription growth, telehealth launch, and AI-driven efficiency drive profitability and focus.

Subscription and AI-driven health insights fuel growth, with FDA clearance as a key differentiator.

2026 outlook prioritizes profitability with raised EBITDA guidance and strong subscription growth.

Record revenue and FDA-cleared status drive growth in pediatric health monitoring.

Record revenue and margin growth in 2025; 2026 outlook strong with global and AI expansion.

Record Q3 results and raised 2025 outlook highlight strong growth and market leadership.

Record Q2 revenue and margins drive raised 2025 outlook amid tariff and warrant restructuring.

Record Q1 revenue and margin growth, with raised 2025 outlook and strong subscription momentum.

Strong retail, international, and medical channel growth, with digital health and subscription expansion.

Record revenue growth and margin expansion position Owlet for 2025 profitability.